Skip to content

EPS (Diluted) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.31+9.2%
CTO
Citius Oncology, Inc.CTOR
-$0.27-145%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$2.15+23.2%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
-$0.15-15.4%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$0.62-313%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$0.98+21.6%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s EPS (diluted)?
TuHURA Biosciences, Inc. (HURA) reported EPS (diluted) of -$0.13 in Q1 2026.
How has TuHURA Biosciences, Inc.'s EPS (diluted) changed year-over-year?
TuHURA Biosciences, Inc.'s EPS (diluted) increased by 13.3% year-over-year, from -$0.15 to -$0.13.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.